<DOC>
	<DOC>NCT00274274</DOC>
	<brief_summary>This trial is conducted in Europe. This trial aims for a comparison of the efficacy and safety of Insulin Aspart, given in a fixed or in a flexible supplementary insulin therapy, with or without Insulin Detemir plus Metformin, if needed, in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 2 Diabetes for more than 6 months Treatment with 1 or more oral antidiabetic drugs or insulin, or a combination of these for more than 3 months Body Mass Index (BMI) less than or equal to 40 kg/m2 HbA1c 7.011.0% Treatment with short acting insulin(s) for longer than 10 days Current treatment with TZDs. A TZD medication must be stopped at least 14 days before the randomization Proliferative retinopathy or maculopathy requiring acute or laser treatment within the last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>